Tianjin Lisheng Pharmaceutical Co.,Ltd.

Sümbol: 002393.SZ

SHZ

25.45

CNY

Turuhind täna

12.3975
P/E suhe
7.8104
PEG suhe
4.64B
MRK Cap
0.01%
DIV tootlus

Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393-SZ) Finantsaruanded

Q: Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on .

Download

Aastane Quarterly

Lineaarne Log

Diagrammil näete Tianjin Lisheng Pharmaceutical Co.,Ltd. (002393.SZ) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist 924.848 M, mis on 0.074 % gowth. Kogu perioodi keskmine brutokasum on 576.694 M, mis on 0.098 %. Keskmine brutokasumi suhtarv on 0.620 %. Ettevõtte eelmise aasta tulemuse puhaskasv on 2.865 %, mis on võrdne 1.149 % % keskmiselt kogu ettevõtte ajaloo jooksul.,

Aastane Quarterly

10Y 20Y 30Y 40Y

Bilanss

Sukeldudes Tianjin Lisheng Pharmaceutical Co.,Ltd. fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja 0. Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus 0.093. Käibevara valdkonnas on 002393.SZ aruandlusvaluutas 2818.535. Märkimisväärne osa neist varadest, täpsemalt 2220.226, hoitakse sularahas ja lühiajalistes investeeringutes. See segment näitab eelmise aasta andmetega võrreldes muutust 0.114%. Ettevõtte pikaajalised investeeringud, kuigi need ei ole tema fookuses, seisavad 1810.597, kui neid on, aruandlusvaluutas. See näitab erinevust 53.362% võrreldes eelmise aruandeperioodiga, mis kajastab ettevõtte strateegilisi muutusi. Ettevõtte võlaprofiil näitab, et ettevõtte pikaajaline koguvõlg on 3.948 aruandlusvaluutas. See näitaja tähendab, et aastane muutus on 0.398%. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud 4903.43 aruandlusvaluutas. Selle aspekti aastane muutus on 0.127%. Kui süveneda ettevõtte finantsnäitajatesse, ilmneb täiendavaid üksikasju. Netovõlad on hinnatud 321.507, varude hind on 176.28 ja firmaväärtus 0, kui see on olemas. Kogu immateriaalne vara, kui see on olemas, hinnatakse 124.86.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006
balance-sheet.row.cash-and-short-term-investments	8384.27	2220.2	1993.6	1651.9	1561.3	1692	1548	1480.1	872.2	980.7	1054.7	1364.3	1357.3	1925.8	2044.3	267.7	120.1	192.2	171.2
balance-sheet.row.short-term-investments	371.13	231.3	200.3	-31.9	-32.7	-37.3	-4	-4.1	0	0	0	-0.1	-1.3	0	0	0	0	0	0
balance-sheet.row.net-receivables	1996.79	321.5	427.7	461.9	435.3	414.3	469.7	310.3	277.3	236.9	266.3	344.4	388.5	310.8	124.5	43.6	35.6	135.8	177.6
balance-sheet.row.inventory	779.47	176.3	199.1	228.8	238.2	278.5	282.5	266.3	242.2	210.2	207.3	206.4	197.7	150.6	161.7	202.5	212.2	256.8	178.7
balance-sheet.row.other-current-assets	449.96	100.5	4.9	13.9	9.5	4.4	1.8	17.1	20.2	22	26.8	-23.4	-28.2	30	-4.2	-0.9	-2.1	-54.2	0.1
balance-sheet.row.total-current-assets	11610.5	2818.5	2625.4	2356.4	2244.4	2389.2	2302	2073.8	1411.9	1449.7	1555.1	1891.7	1915.3	2417.1	2326.3	512.8	365.8	530.5	527.5
balance-sheet.row.property-plant-equipment-net	4045.76	981.9	1029.8	1136.7	1087.6	1114.3	1124.5	1131.4	1643	1554.9	1265.4	921.3	586	277.4	198.7	169.1	163.4	160.4	166.7
balance-sheet.row.goodwill	57.92	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.intangible-assets	567.45	124.9	135.5	144.2	148.1	159.8	170.2	156.6	106.8	109	111.8	111.8	114.8	112.4	100.7	102.4	106.4	62.9	47.5
balance-sheet.row.goodwill-and-intangible-assets	625.37	124.9	135.5	144.2	148.1	159.8	170.2	156.6	106.8	109	111.8	111.8	114.8	112.4	100.7	102.4	106.4	62.9	47.5
balance-sheet.row.long-term-investments	6115.65	1810.6	1180.6	1531.8	1517.4	1592.2	298.1	308.3	305.9	232.2	233.5	229.3	224.1	0	0	0	0	0	0
balance-sheet.row.tax-assets	134.98	39.5	33.7	16.3	6.6	7.2	2.8	2.6	8.9	2.3	2	1.8	1.3	0.2	0.2	1.3	0.2	0.8	1.4
balance-sheet.row.other-non-current-assets	177.12	5.3	286.1	5.5	18.1	10.1	19.6	9.4	9.2	61.4	79.9	66.3	93.3	55.1	101.4	96.5	109.5	119.5	120.4
balance-sheet.row.total-non-current-assets	11098.87	2962.1	2665.6	2834.5	2777.8	2883.5	1615.2	1608.3	2073.9	1959.7	1692.7	1330.4	1019.5	445.1	400.9	369.3	379.5	343.6	336
balance-sheet.row.other-assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-assets	22709.37	5780.6	5291	5190.9	5022.2	5272.7	3917.2	3682	3485.7	3409.4	3247.8	3222.1	2934.7	2862.2	2727.2	882.1	745.4	874.1	863.5
balance-sheet.row.account-payables	331.1	84.8	146.4	90.5	128.3	112.8	111.4	149.3	212	229.8	136.6	79.7	57.9	17.5	11.3	7.8	21.4	23.7	15.1
balance-sheet.row.short-term-debt	228.64	59.1	39.7	28.5	19.2	26.9	81.2	80	61.4	50	40	48	0	0	20	180	146.4	171.2	94.9
balance-sheet.row.tax-payables	149.6	14.6	42.5	20.3	10.1	21.3	33.2	11	13.6	8.1	7.5	-2.7	18.9	12.6	19.7	-0.4	-10.5	-1.1	-3.8
balance-sheet.row.long-term-debt-total	17.77	3.9	5.4	6.2	6	0	0	10	30	50	70	90	8	0	0	0	19.5	37.9	56.4
Deferred Revenue Non Current	117.89	27.9	31.8	31.7	29.1	26.8	18.7	11.3	17.9	15.5	14.4	0	0	0	0	3.3	0	0	-56.4
balance-sheet.row.deferred-tax-liabilities-non-current	741.36	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.other-current-liab	1093.6	467.4	543.9	1.4	2.6	27.9	459	17.3	13.6	3.1	3.7	7.3	76.1	40.4	10.3	208.1	72.5	174	147.5
balance-sheet.row.total-non-current-liabilities	906.67	223	211.7	228	217.3	215.5	20.1	23.7	51.5	70.2	90.3	107.2	14.1	6.1	6.1	3.3	19.5	37.9	58.4
balance-sheet.row.other-liabilities	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.capital-lease-obligations	17.77	3.9	5.4	6.2	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.total-liab	3750.51	849.2	941.7	780.4	720.1	855.9	704.8	602.3	470.6	439.5	337.9	298.2	148.1	64.1	77.1	411.3	270.6	441.9	415
balance-sheet.row.preferred-stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.common-stock	736.51	184.3	184	182.5	182.5	182.5	182.5	182.5	182.5	182.5	182.5	182.5	182.5	182.5	182.5	136.5	136.5	136.5	136.5
balance-sheet.row.retained-earnings	5422.19	1393.7	1126.6	1098	1005.3	1058.6	946.7	832.8	781.3	745.5	698.3	728.5	605	353.1	225.1	42.1	94.6	93	117.4
balance-sheet.row.accumulated-other-comprehensive-income-loss	9405.31	1612	1328.7	1439.4	1423.7	1485.1	0	0	0	0	0	0	0	0	0	0	0	0	0
balance-sheet.row.other-total-stockholders-equity	3334.68	1713.4	1710.1	1690.7	1690.7	1690.7	2083.2	2064.4	2051.4	2042	2029.1	2012.9	1984.3	2252.4	2219.9	238.3	201.4	172	164
balance-sheet.row.total-stockholders-equity	18898.68	4903.4	4349.4	4410.5	4302.1	4416.8	3212.4	3079.7	3015.2	2969.9	2909.9	2923.8	2771.7	2787.9	2627.5	416.8	432.5	401.4	417.9
balance-sheet.row.total-liabilities-and-stockholders-equity	22709.37	5780.6	5291	5190.9	5022.2	5272.7	3917.2	3682	3485.7	3409.4	3247.8	3222.1	2934.7	2862.2	2727.2	882.1	745.4	874.1	863.5
balance-sheet.row.minority-interest	32.24	0	0	0	0	0	0	0	0	0	0.1	0.1	14.9	10.2	22.6	54	42.3	30.8	30.6
balance-sheet.row.total-equity	18930.92	4903.4	4349.4	4410.5	4302.1	4416.8	3212.4	-	-	-	-	-	-	-	-	-	-	-	-
balance-sheet.row.total-liabilities-and-total-equity	22709.37	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Investments	6486.78	2041.9	1380.9	1499.8	1484.7	1554.9	294.1	304.2	305.9	232.2	233.5	229.3	222.8	53.6	99.6	94.4	107.2	116.9	120.4
balance-sheet.row.total-debt	246.41	63	45.1	34.7	19.2	26.9	81.2	90	91.4	100	110	138	8	0	20	180	165.9	209	151.3
balance-sheet.row.net-debt	-7705.06	-1925.9	-1748.2	-1617.2	-1542.2	-1665	-1466.8	-1390.1	-780.8	-880.7	-944.7	-1226.3	-1349.2	-1925.8	-2024.3	-87.7	45.8	16.9	-19.9

Rahavoogude aruanne

Tianjin Lisheng Pharmaceutical Co.,Ltd. finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab -0.491 nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides 0, mis tähistab 0.154 erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli 9859240.000. See on -1.063 nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte 67.31, 0, 0, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid 0.000, kusjuures erinevus võrreldes eelmise aastaga oli 0.000. Lisaks eraldas ettevõte -54.74 aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui 5.91, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006
cash-flows.row.net-income	374.48	361.8	93.6	122.1	8.6	188.1	185	116.8	115.6	114.2	92.9	298.1	301.7	333.4	219.3	166.3	143.5	132	100.2
cash-flows.row.depreciation-and-amortization	-0.02	67.3	66.1	60.2	63.5	60.8	54.8	56.4	49.1	25.4	25.8	24	25	16.8	17.2	17.5	17.1	15	0
cash-flows.row.deferred-income-tax	-36.38	-5.5	-15.4	-8.7	1.4	-4.3	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.stock-based-compensation	8.97	-136.5	15.4	8.7	-1.4	4.3	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.change-in-working-capital	29.92	1.6	137.9	17.6	-51.2	21.2	-54.6	24.5	-1.3	55.9	-44.8	-10.2	-72.5	-118.1	-49.9	-4.5	-47.9	26.6	0
cash-flows.row.account-receivables	17.52	17.5	25.1	-19.5	-4.3	-44.9	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.inventory	8.91	8.9	11.1	-4.4	29.9	-3.9	-19.5	-32.8	-34.5	-0.9	-4.4	-9.1	2.3	8.9	40.9	8.4	44.5	-77.5	0
cash-flows.row.account-payables	0	-28.3	117	50.2	-78.2	74.3	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.other-working-capital	3.49	3.5	-15.4	-8.7	1.4	-4.3	-35.1	57.2	33.2	56.8	-40.4	-1.1	-74.8	-127	-90.7	-12.9	-92.4	104.2	0
cash-flows.row.other-non-cash-items	-128.58	-79.3	33.8	-3.6	55.5	-1.8	-22.5	-18.5	10.2	2.6	-1.7	-22.2	-3.5	-97.6	-0.1	17	14	1.4	-100.2
cash-flows.row.net-cash-provided-by-operating-activities	245.52	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.investments-in-property-plant-an-equipment	-59.66	-61.7	-40.9	-88.2	-100.7	-90.5	-104.4	-50.1	-137.2	-204.6	-290.6	-313.1	-224.3	-165.9	-69.7	-17.6	-64.9	-13.9	-30.8
cash-flows.row.acquisitions-net	147.74	151.5	115.3	0.1	100.8	0.1	0	-2.2	0.9	0	0	0	225	166	2.5	0	64.9	14.3	32.9
cash-flows.row.purchases-of-investments	-580	-470	-320	-70	-0.8	-0.1	-700	0.1	-75	0	0	0	-29.4	-4.2	-42.8	0	-31	-356.3	-190
cash-flows.row.sales-maturities-of-investments	339.7	390	90	82	8.4	24.3	739.1	18.5	16.2	10.5	3.5	37.6	48.2	120.7	2.2	1	85.1	275.6	293.9
cash-flows.row.other-investing-activites	31.53	0	0	0	-100.7	0.1	1.5	528.9	8.6	20.1	10	18.5	-224.3	-165.9	-0.4	1.8	-64.9	-13.9	-30.8
cash-flows.row.net-cash-used-for-investing-activites	-120.69	9.9	-155.6	-76.1	-92.9	-66	-63.9	495.2	-186.5	-174	-277.1	-257	-204.8	-49.4	-108.2	-14.8	-10.7	-94.2	75.1
cash-flows.row.debt-repayment	-22.45	0	-0.1	0	-40	-30	-55	-42	-50	-40	-76.5	0	0	-20	-250	-367.1	-401.1	-102.2	-361.1
cash-flows.row.common-stock-issued	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.common-stock-repurchased	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.dividends-paid	-6.29	-54.7	-54.7	-18.2	-55.1	-55.9	-57.3	-58.3	-77.2	-58.3	-111.5	-162.1	-158	-164.5	-150.7	-47.9	-144.8	-107.5	-32.8
cash-flows.row.other-financing-activites	-65.85	5.9	21	0	20	20	20	37	22.5	30.8	52.6	136.5	-501.7	-21.1	2099	381.2	357.9	150	336
cash-flows.row.net-cash-used-provided-by-financing-activities	-143.04	-48.8	-33.8	-18.2	-75.1	-65.9	-92.3	-63.3	-104.7	-67.5	-135.4	-25.6	-659.7	-205.6	1698.3	-33.7	-188	-59.7	-57.9
cash-flows.row.effect-of-forex-changes-on-cash	30.37	25.1	0	0	0	0	0.1	0	0	0	0	0	0	0	0	0	0	0	0
cash-flows.row.net-change-in-cash	-7.46	195.7	142	102	-91.6	136.4	6.6	611.2	-117.6	-43.4	-340.3	7	-613.8	-120.4	1776.6	147.6	-72	21	-17.5
cash-flows.row.cash-at-end-of-period	7910.84	1989	1769.6	1627.7	1525.7	1617.3	1480.9	1474.3	863.1	980.7	1024	1364.3	1357.3	1923.9	2044.3	267.7	120.1	192.2	171.2
cash-flows.row.cash-at-beginning-of-period	7918.29	1793.3	1627.7	1525.7	1617.3	1480.9	1474.3	863.1	980.7	1024	1364.3	1357.3	1971.1	2044.3	267.7	120.1	192.2	171.2	188.6
cash-flows.row.operating-cash-flow	245.52	209.5	331.4	196.3	76.4	268.3	162.7	179.2	173.6	198.1	72.2	289.6	250.7	134.6	186.6	196.1	126.6	174.9	0
cash-flows.row.capital-expenditure	-59.66	-61.7	-40.9	-88.2	-100.7	-90.5	-104.4	-50.1	-137.2	-204.6	-290.6	-313.1	-224.3	-165.9	-69.7	-17.6	-64.9	-13.9	-30.8
cash-flows.row.free-cash-flow	185.86	147.8	290.5	108.1	-24.3	177.9	58.3	129.2	36.4	-6.5	-218.4	-23.5	26.4	-31.4	116.9	178.5	61.7	161	-30.8

Kasumiaruande rida

Tianjin Lisheng Pharmaceutical Co.,Ltd. tulud muutusid võrreldes eelmise perioodiga -0.014%. 002393.SZ brutokasum on teatatud 634.54. Ettevõtte tegevuskulud on 521.92, mille muutus võrreldes eelmise aastaga on -9.523%. Kulud amortisatsioonikulud on 67.31, mis on 0.018% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud 521.92, mis näitab -9.523% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on 0, mis on 0.000% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on 0, mis tähendab -0.359% kasvu võrreldes eelmise aastaga. Tegevustulu on 112.62, mis näitab -0.359% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on 2.865%. Eelmise aasta puhaskasum oli 361.83.

common:word.in-mln USD Growth	TTM	2022	2020	2018	2016	2014	2012	2010	2008	2006
income-statement-row.row.total-revenue	1170.61	1130.2	1146.6	1091.9	1140.8	1615.3	1503.6	1029.4	846.9	774.8	773.7	1044.4	1117.1	763.6	738	595.7	592.5	393.3	349.4
income-statement-row.row.cost-of-revenue	515.47	495.6	486.3	454.5	439.5	447.8	427.1	378.7	365.4	346.5	347.1	369.4	428.4	299.5	295.4	218.3	241.4	119.9	105.9
income-statement-row.row.gross-profit	655.14	634.5	660.3	637.5	701.3	1167.5	1076.5	650.7	481.4	428.3	426.6	675	688.7	464.1	442.6	377.4	351.1	273.4	243.5
income-statement-row.row.gross-profit-ratio	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
income-statement-row.row.research-development	103.47	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-general-administrative	24.94	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.selling-and-marketing-expenses	314.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-expenses	-29.02	-13.8	108.4	96.1	113.1	121.7	-1	0.2	2	2	4.4	5.5	5.3	0.9	3.6	6.4	0.3	1	0.7
income-statement-row.row.operating-expenses	564.73	521.9	576.8	591.8	643.3	971.5	903.1	552.4	366.2	299.8	338.3	370.2	366.8	222.3	199.6	165.4	162.7	118.5	136.5
income-statement-row.row.cost-and-expenses	1080.2	1017.5	1063.1	1046.3	1082.8	1419.3	1330.3	931.1	731.6	646.3	685.5	739.6	795.2	521.8	495	383.7	404.2	238.4	242.4
income-statement-row.row.interest-income	-29.87	61.2	68.3	87.6	28.5	22.4	20.7	14.1	26.9	7.7	18.1	21.2	33.4	46.9	20.8	0.8	0.8	0	0
income-statement-row.row.interest-expense	1.54	0.9	0.9	0.3	0.5	1.4	2.7	3.5	2.5	1.7	2	0.2	0.1	0.2	2	4.3	8.5	5.9	4.9
income-statement-row.row.selling-and-marketing-expenses	314.2	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.total-other-income-expensenet	49.9	296.6	-57.3	0.2	-71.4	-3.4	40.6	32.5	18.1	6.9	23.8	48.3	41.2	144.9	22.1	-10.4	-15.9	0.8	10.9
income-statement-row.row.ebitda-ratio-caps	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.other-operating-expenses	-29.02	-13.8	108.4	96.1	113.1	121.7	-1	0.2	2	2	4.4	5.5	5.3	0.9	3.6	6.4	0.3	1	0.7
income-statement-row.row.total-operating-expenses	49.9	296.6	-57.3	0.2	-71.4	-3.4	40.6	32.5	18.1	6.9	23.8	48.3	41.2	144.9	22.1	-10.4	-15.9	0.8	10.9
income-statement-row.row.interest-expense	1.54	0.9	0.9	0.3	0.5	1.4	2.7	3.5	2.5	1.7	2	0.2	0.1	0.2	2	4.3	8.5	5.9	4.9
income-statement-row.row.depreciation-and-amortization	-194.14	67.3	66.1	75.8	63.5	84.3	54.8	56.4	49.1	25.4	25.8	24	25	16.8	17.2	17.5	17.1	15	-12.4
income-statement-row.row.ebitda-caps	175.88	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
income-statement-row.row.operating-income	370.02	112.6	175.7	136.9	102.4	220.1	215	130.6	131.3	133.6	107.8	348	358	386	261.5	195.3	172.4	154.7	117.3
income-statement-row.row.income-before-tax	419.92	409.2	118.4	137.1	30.9	216.8	214	130.8	133.3	135.4	112.1	353.2	363.1	386.8	265.1	201.6	172.5	155.7	117.9
income-statement-row.row.income-tax-expense	57.56	58.4	24.8	15	22.3	28.7	29	14	17.7	21.2	19.2	55.1	61.3	53.4	45.8	35.3	29.1	23.7	19
income-statement-row.row.net-income	374.48	361.8	93.6	122.1	8.6	188.1	185	116.8	115.6	114.2	92.9	298.1	297.1	324.8	203.4	154.5	132	132.4	100.2